5:49 PM
 | 
Dec 26, 2012
 |  BC Extra  |  Top Story

FDA approves lomitapide for hoFH

FDA approved Juxtapid lomitapide from Aegerion Pharmaceuticals Inc. (NASDAQ:AEGR) on Monday to treat patients with homozygous familial hypercholesterolemia (hoFH). The small molecule microsomal triglyceride transfer protein (MTP) inhibitor is approved as an adjunct to a low-fat diet and other lipid-lowering therapies, including LDL apheresis where available, to reduce LDL-C, total cholesterol, apolipoprotein B (APOB) and non-HDL-C in hoFH patients. Aegerion said it plans...

Read the full 309 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >